Ramez Smairat, MD
Interventional Cardiology · Manhattan, KSNPI 1841599628
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (50.1%), other and travel and lodging — rather than concentrated in one kind of arrangement. 32 manufacturers reported payments, led by Abbott at 31.9% of the total. Reporting peaked in 2024 at $4,070 and has fallen 77.3% since, to $922 in 2025.
Across 253 payments — averaging $45.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$4K
- Angiodynamics, Inc.$3K
- Inari Medical, Inc.$600
- Novartis$427
- Shockwave Medical, Inc$423
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$402
- plus $3K from 26 others
What the payments were for
- Travel & lodging$2,48422%
- Food & beverage$5,74450%
- Education$2362%
- Other$3,00026%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 25 | $3,662 |
| Angiodynamics, Inc. | 2 | $3,000 |
| Inari Medical, Inc. | 13 | $600 |
| Novartis | 34 | $427 |
| Shockwave Medical, Inc | 7 | $423 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 30 | $402 |
| Boston Scientific | 15 | $329 |
| Stryker | 6 | $312 |
| Medtronic(2 entities) | 12 | $301 |
| Abiomed | 11 | $285 |
| Amgen | 18 | $263 |
| AstraZeneca | 16 | $239 |
| Astellas Pharma US Inc | 2 | $198 |
| Johnson & Johnson | 12 | $175 |
| Pfizer | 9 | $131 |
| Boehringer Ingelheim | 5 | $73 |
| Actelion Pharmaceuticals US, Inc. | 4 | $71 |
| E.r. Squibb & Sons, L.L.C. | 3 | $71 |
| Regeneron Healthcare Solutions, Inc. | 4 | $67 |
| Bridgebio Pharma, Inc. | 2 | $57 |
| Cvrx, Inc. | 2 | $52 |
| Amarin Pharma, Inc. | 3 | $49 |
| Sanofi-aventis U.S. LLC | 3 | $42 |
| Baxter Healthcare | 2 | $39 |
| Kowa Pharmaceuticals America, Inc. | 3 | $38 |
| Merck | 2 | $30 |
| Gilead | 2 | $28 |
| Bardy Diagnostics, Inc. | 2 | $25 |
| Bayer | 1 | $20 |
| Cardinal Health 200 LLC | 1 | $19 |
| Philips North America LLC | 1 | $19 |
| Daiichi Sankyo Inc. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$11,465 in reported general payments places this provider in the 55th percentile of 55 interventional cardiology providers in Kansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 209 | $125,567 |
| XareltoRivaroxaban | 103 | $80,693 |
| JardianceEmpagliflozin | 57 | $39,605 |
| Repatha SureclickEvolocumab | 49 | $27,849 |
| EntrestoSacubitril/Valsartan | 20 | $13,735 |
| BrilintaTicagrelor | 11 | $4,852 |
| Atorvastatin Calcium | 460 | $4,504 |
| Diltiazem 12hr ErDiltiazem Hcl | 12 | $3,461 |
| Ranolazine ErRanolazine | 65 | $2,531 |
| Metoprolol Succinate | 163 | $2,198 |
| Carvedilol | 191 | $1,790 |
| Losartan Potassium | 132 | $1,630 |
| ClopidogrelClopidogrel Bisulfate | 112 | $1,590 |
| Rosuvastatin Calcium | 133 | $1,409 |
| Pantoprazole Sodium | 94 | $1,294 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $131 | $125,567209 claims |
| Johnson & JohnsonXarelto | $175 | $80,693103 claims |
| Boehringer IngelheimJardiance | $73 | $39,60557 claims |
| NovartisEntresto | $427 | $13,73520 claims |
| AstraZenecaBrilinta | $239 | $4,85211 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 55 interventional cardiology providers in Kansas.
Other interventional cardiology in Manhattan
- Priyantha RanaweeraManhattan$41K
- William FreundManhattan$947
- Anthony SpaedyKansas City$385K
- Prasad GunasekaranKansas City$76K
- Maheedhar GedelaWichita$54K
- Kamal GuptaKansas City$46K
- Mark WileyKansas City$39K
- Ahmed SoukaTopeka$37K
- Pouyan ArmanOverland Park$33K
- John SerfasKansas City$31K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.